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Background: Intra-articular injections of platelet-rich plasma (PRP) to treat symptoms of knee osteoarthritis (OA) have been
successfully used in young patients and in the early stages of disease. No previous studies have analyzed outcomes of PRP
injections during the late stages.
Hypothesis: PRP reduces pain and leads to a more effective and lasting functional recovery than corticosteroid with local
anesthetic.
Study Design: Randomized controlled trial; Level of evidence, 2.
Methods: A total of 75 patients with symptomatic knee OA (Kellgren-Lawrence grade 3 to 4) were enrolled in this study between
August 2013 and July 2014. Patients were randomized to treatment either with a single leukocyte-reduced PRP or corticosteroid
intra-articular injection. The primary variable was visual analog scale assessment at 1 month. Secondary outcomes were the Knee
injury and Osteoarthritis Outcome Score (KOOS) and Short Form–36 (SF-36) at 1, 3, and 6 months after treatment. Patient
satisfaction at final follow-up was assessed. Both groups were homogeneous and comparable in baseline characteristics.
Results: All variables improved in both groups. Statistical differences between groups were not found for the majority of the
outcome variables, although the magnitude of improvements tended to be greater in the PRP group. Quality-of-life differences
between values at 3 and 6 months versus baseline increased significantly more in the study group (P ¼ .05 and .03, respectively),
and so did general health perception differences at 6 months (P ¼ .018).
Conclusion: A single PRP intra-articular injection is effective for relieving pain and improving activities of daily living and quality of
life in late-stage knee OA. For patients with late-stage knee OA who are 67 years or older, 1 intra-articular injection of PRP has
similar results to 1 shot of corticosteroid.
Keywords: platelet-rich plasma; osteoarthritis; knee; intra-articular injections
Osteoarthritis (OA) is the most common joint disease in the
world and a major cause of pain and disability in older
adults.24 Analysis from primary care databases of different
countries found higher incidence of knee OA than hip or
hand OA and a large increase in newly diagnosed cases of
knee OA in the past decade, especially in younger
adults.1,26,34 The main symptom of patients with knee OA
is pain, often accompanied by stiffness and limited mobility
of the knee.
Initial OA treatment combines nonpharmacological
methods with oral medications. In more advanced or very
symptomatic stages, intra-articular injection (IAI) is used:
corticosteroid with local anesthetic (CSA), hyaluronic acid
(HA), or biological products such as platelet-rich plasma
(PRP). However, current studies have changed the pre-
scribing pattern, using IAI as a first-line treatment because
it has proven effectiveness for pain with fewer side effects
than some oral medications.2,3,9,10,14,16,28 The use of PRP in
the treatment of degenerative knee OA has been extended
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in recent years given its high margin of safety and easy
production and administration.30 Published studies regard-
ing PRP IAI for knee OA have varying levels of scientific
evidence.4,5,7,18,22,31 Usually they note the effectiveness of
PRP for pain treatment and knee joint function, its superi-
ority compared with HA or placebo, and its better results in
the early stages of knee OA. In addition, compared with HA,
its effects last longer (6-12 months). Published clinical trials
also confirm the superiority of PRP in comparison with other
IAIs.6,25,27,29,30,32 Nearly all published data have found good
results in young patients and in early-stage knee OA, but no
previous studies have analyzed the clinical outcomes of PRP
injections during the late stages of disease.
The hypothesis of this study was that PRP reduces pain
and leads to a more effective and lasting functional recov-
ery compared with CSA. Our objective was to compare the
efficacy of a single PRP IAI for relieving pain and improving
knee function during late-stage OA with a CSA IAI. We
have compared PRP with CSA rather than placebo so as
not to leave any patient untreated (in previous published
trials, placebo has been shown to be unsuccessful30). For
this reason, we considered CSA to be the gold standard for
pain treatment through IAI in late-stage knee OA.
METHODS
Trial Design
This was a prospective randomized, double-blind, parallel
group, active-controlled study with 2 groups receiving dif-
ferent treatments. This clinical trial was conducted in
accordance with the principles of the Declaration of
Helsinki, authorized by the Spanish Agency for Medicines
and Health Products, and registered with the European
Clinical Trials Database.
Volunteer participants were assigned to 1 of 2 interven-
tion groups and assessed on a number of variables before
and at 3 points after treatment (1, 3, and 6 months). We
decided to perform the first assessment at 4 weeks after the
infiltration, assuming clinical improvement after cortico-
steroid injection has an effect between 1 and 4 weeks. The
reason not to extend the study beyond 6 months was to
prevent patients from having to wait a year to receive a
new treatment, if necessary. Note that most publications
observed symptomatic deterioration from the sixth month
in patients treated with PRP and from the first month in
patients treated with CSA.3,5,7,13,16,18-23,31
Sample
Sample size calculation was performed using the hypothesis
of superiority. In the assessment of pain by visual analog
scale (VAS) (range, 0-100 points) 1 monthafter the procedure,
we assumed an average score of 33.7 in the control group and
a standard deviation of 23.6 in both groups. To detect a reduc-
tion of 17 points in the treatment group versus the control
group with a power of 80% and 2-sided significance level of
.05, it would be necessary to include a total of 64 patients (32
patients per group). A difference of 17 points between the 2
groups was fixed based on published results.19,20 The sample
size calculation was performed using 2008 PASS (NCSS Sta-
tistical Software). Statistical data analysis was carried out
using SPSS (version 17.0.2; IBM Corp).
Categorical variables were described by percentages and
frequencies, while continuous variables were described by
means, standard deviations, medians, interquartile ranges,
and minimum and maximum values. The analysis of pri-
mary and secondary variables was accomplished using the
intention to treat principle. Parametric tests (Student t test
for independent samples) were used for normal distribu-
tions and the Mann-Whitney U test for nonparametric dis-
tributions. Data symmetry was analyzed using the
Shapiro-Wilk test. If the P value was not significant, then
the Student t test was used. Otherwise, the Mann-Whitney
U test was used. Categorical variables were compared
using chi-square tests. The level of statistical significance
was set at P < .05.
TABLE 1




Eligibility for total knee arthroplasty
Walking ability with or without external support
Visual analog scale baseline value >60
Informed consent obtained
Exclusion criteria
Inability to obtain informed consent
Received intra-articular injections of steroids, anesthetics, or
hyaluronic acid in the past year
Underwent arthroscopic surgery in the past 3 months
Received open surgery on occasion




Clotting deficiency (blood dyscrasias)









Severe damage of homolateral hip or ankle
Rheumatoid arthritis
Inflammatory diseases of the connective tissue
Involved in proceedings for legal incapacitation or financial
compensation
Documented history of allergy to steroids, bupivacaine, or blood
products
Valgus deformity >15 or varus deformity >20
Severe ligamentous instability of the knee joint
Limitation of knee range of movement: flexion <90,
extension deficit >20
Positive serology
aAs diagnosed by the American College of Rheumatology.28
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Data were collected and entered into a database by our
Unit in Methodology for Biomedical Research (USMIB).
Participants
The study population consisted of patients already on the
waiting list of the public health system for knee replace-
ment. OA was diagnosed by the American College of Rheu-
matology criteria33 and staged as Kellgren-Lawrence (K-L)
radiological classification.17 All radiographs were taken
under weightbearing conditions. Patients who met eligibil-
ity criteria (Table 1) and signed consent to participate in the
clinical trial were allocated (computer random sequence
generated by USMIB) to 1 of 2 intervention groups: the
study group (4 mL autologous PRP) or the control group
(2 mL betamethasone: 6 mg betamethasone sodium phos-
phate and betamethasone acetate 6 mg [Merck] and 2 mL
bupivacaine 0.25% [B.Braun]). Before treatment assign-
ment, blood collection was performed for serological study.
Patients with positive serology for HIV, hepatitis, or syph-
ilis were discarded. All patients were blinded to the treat-
ment they received.
All included patients provided a 60-mL sample of periph-
eral blood. Blood of patients assigned to the control group
was discarded. Blood of patients assigned to the study
group was analyzed and prepared according to the protocol
of the hospital blood and tissue bank (BST).
PRP Preparation
The BST prepared leukocyte-reduced PRP using a double-
spin methodology. The entire process was performed in a
class C clean room and under the laminar flow of a BioII/A
biological safety cabinet (LAbGard; Nuaire). Approxi-
mately 60 mL of venous blood was drawn from the antic-
ubital vein and collected into tubes containing 3.2% of
citrated dextrose as an anticoagulant (Becton Dickinson
Biosciences). Tubes were then centrifuged at 280g for
15 minutes at room temperature on a table-top centrifuge,
the entire plasmatic fraction was isolated in a separate
sterile tube avoiding the buffy coat layer, and a 10% vol/vol
of anticoagulant (ACD-A Solution; Grifols) was added. The
isolated plasma was centrifuged at 680g for 20 additional
minutes, and platelets were then completely resuspended
in 6 mL of autologous plasma. Finally, 4 mL of PRP were
dispensed in a syringe for further injection, and the remain-
der volume was dedicated to count platelets and white
blood cells (WBC) in a hematology analyzer (AcT diff2;
Beckman Coulter). We did not use exogenous factors for the
activation process.
Intervention Procedure
Under aseptic conditions, 4 mL of either control or study
treatment were injected into the medial compartment
with an intramuscular needle (0.8  40 mm) without local
anesthetic, with knees hanging at 90 of flexion. Rest,
depending on pain, and cryotherapy were indicated in the
first 24 hours after injection. Patients were authorized to
use painkillers and nonsteroidal anti-inflammatories
along with routine clinical practice during the study
period. This did not invalidate the study, as both groups
were authorized.
Patients were monitored 1 week after injection to rule
out side effects of the infiltration and returned at 1, 3, and
6 months after treatment.
Randomized (n = 65)
Patients assessed for eligibility (N = 169)Enrollment
Excluded  (n = 104)
♦ Not meeting inclusion criteria (n = 94)
♦ Decline to participate (n = 8)
♦ Other reasons (n = 2)
Allocated to receive PRP (n = 35)
♦ Received allocated intervention (n = 35)
♦ Did not receive allocated intervention (n = 0)
Allocated to receive PRP (n = 30)
♦ Received allocated intervention (n = 30)
♦ Did not receive allocated intervention (n = 0)
Lost to follow-up (not attend control visits) (n = 1)
Discontinued intervention (n = 0)
Lost to follow-up (n =0)
Discontinued intervention (n = 0)
Analyzed (n = 34)
♦ Excluded from analysis (n = 0)
Analyzed (n = 30)




Figure 1. CONSORT (Consolidated Standards of Reporting Trials) flow diagram. PRP, platelet-rich plasma.
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TABLE 2
Baseline Characteristics of Study Subjectsa
Treatment Group
P ValuePRP Control







Sex (female/male), n (%) 23/12 (65.71/34.29) 24/6 (80/20) .269
Smoker (no/yes), n (%) 29/6 (82.86/17.14) 26/4 (86.67/13.33) .742
External support to walk (no/yes), n (%) 34/1 (97.14/2.86) 29/1 (96.67/3.33) >.999
Knee Society patient category, (No. of knees) %c .730
A 8 (22.86) 5 (16.67)
B 25 (71.43) 24 (80)
C 2 (5.71) 1 (3.33)
Side (right/left), n (%) 16/19 (45.71/54.29) 14/16 (46.67/53.33) >.999
K-L classification, n (%) .026
Grade 1 0 (0) 0 (0)
Grade 2 0 (0) 0 (0)
Grade 3 10 (28.6) 17 (56.6)
Grade 4 25 (71.4) 13(43.4)







Use of pain medication, n (%) .63
Analgesics 18 (48.65) 19 (51.35)
NSAIDs 18 (52.94) 16 (47.06)
Opiates 4 (57.14) 3 (42.86)
Range of motion, degb
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To keep the process double-blinded, BST prepared both
treatments in an opaque syringe. To decrease bias, the
same person performed all injections.
Outcome Measures
Pain VAS scores at 1 month (change from baseline) was
considered the primary outcome variable. Secondary vari-
ables were VAS, functional knee evaluated with the Knee
injury and Osteoarthritis Outcome Score (KOOS), and
quality of life evaluated with the Short Form–36 (SF-36)
at 1, 3, and 6 months after treatment. Other goals were to
evaluate the correlation between PRP clinical effect on pain
and platelet concentration of the infiltrated product and the
degree of patient satisfaction at final follow-up.
Demographic variables (age, sex, body mass index [BMI])
and degree of radiological involvement were also collected.
Mobility of the knee joint (flexion and extension), use of
analgesics or nonsteroidal anti-inflammatory drugs, and
VAS, KOOS, and SF-36 outcomes were evaluated before
and at 1, 3, and 6 months after treatment by a blinded
observer.
The type and severity of all adverse events presented
during the study and appreciation of their relationship to
treatment were collected. Platelet and leukocyte concentra-
tions in the PRP injection were determined.
RESULTS
Between August 2013 and July 2014, a total of 34 patients












































8.33 [ 0.00, 25.00]
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aBMI, body mass index; K-L, Kellgren-Lawrence; KOOS, Knee injury and Osteoarthritis Outcome Scale; NSAID, nonsteroidal anti-
inflammatory drug; PRP, platelet-rich plasma SF-36, Short Form–36; VAS, visual analog scale.
bData are provided as mean ± SD (range) and median [25th percentile, 75th percentile], unless indicated otherwise.
cKnee Society clinical rating system: A ¼ unilateral or bilateral (opposite knee successfully replaced); B ¼ unilateral, other knee symp-
tomatic; C ¼ multiple arthritis or medical infirmity.
TABLE 3
Patient Satisfaction at 6 Monthsa
Treatment Group
Patient Satisfaction, % PRP Control
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were enrolled and observed (Figure 1). The PRP contained
a median value of 0.99  106 platelets/mL (range, 0.34-1.54
 106 platelets/mL) and a median value of 0.6 106 WBC/mL
(range, 0.1-1.8 106 WBC/mL) (LP-PRP: PAW classification
system type 3B8). The 2 groups did not differ in any of the
qualitative variables collected at baseline except for OA
grade and SF-36 general health perception subscale, which
were worse for the PRP group (Table 2).
No patient had adverse effects at injection or follow-up.
No differences were found in the use of painkillers and
nonsteroidal anti-inflammatories or dose or frequency
between groups at any time point. At 6 months, patient
satisfaction tended to be higher in the study group; how-
ever, we were unable to find statistically significant differ-
ences (P ¼ .472) (Table 3).
VAS score decreased for both groups, with no significant
differences between groups at different time points (Table
4). The differences in VAS score at 1, 3, and 6 months com-
pared with baseline showed no statistically significant dif-
ferences between groups (P ¼ .568, .623, and .568,
respectively). Considering that there were no significant
differences at baseline for VAS, the difference tended to
be greater in the PRP group (Figure 2).
KOOS outcomes are presented in Table 5. The difference
magnitude between baseline and subsequent follow-ups
tended to be greater in the PRP group for each of the dimen-
sions, but these differences were not significant (Figure 3). The
differences in KOOS–Quality of Life scores between baseline
and 3 and 6 months increased significantly more in the PRP
than in the control group (mean, 17.77 vs 4.91 at 3 months and
16.88 vs 3.56 at 6 months; P ¼ .05 and .03, respectively).
The SF-36 scores are presented in Table 6. The improve-
ment in SF-36 general health perception score between
baseline and 6 months was greater in the PRP than the
control group (4.25 vs 4.92; P ¼ .018).
There was no correlation between the concentration of
platelets infiltrated into the joint and the VAS change from
baseline at 1, 3, and 6 months (P ¼ .41, .70, and .43, respec-
tively), nor was there a difference found in relation to WBC
concentration (P ¼ .75, .67, and .40, respectively).
DISCUSSION
The results obtained in our study did not confirm our
hypothesis with sufficient statistical value. Although we
found that a single PRP IAI reduces pain, we could not
prove its superiority in terms of effectiveness and lasting
pain relief compared with CSA.
Most published works regarding the effectiveness of PRP
IAI for the treatment of OA are series studies, with an
average age less than 60 years and patients with early-
stage OA. In the series by Kon et al19,20 comparing PRP
with HA at 6-month follow-up, the best results from the
International Knee Documentation Committee question-
naire, VAS, and degree of patient satisfaction were
achieved in the PRP group (P < .005), especially for younger
patients, males, and those with early-stage OA. According
to the systematic review by Meheux et al,23 most of the
studies included early-stage OA, with grades 3 and 4 being
less common (9.4% of the knees were Ahlback grade 3,
37.9% K-L grade 3, and 12.6% K-L grade 4). In these stud-
ies, the worst results were obtained for K-L grades 3 to 4.
TABLE 4
VAS Score Compared With Baseline at Each Follow-up for Both Groupsa
Baseline 1 mo














3 mo 6 mo














aData are provided as mean ± SD (range) and median [25th percentile, 75th percentile]. PRP, platelet-rich plasma; VAS, visual analog
scale.
Figure 2. Trends in mean pain visual analog scale (VAS)
scores of both groups at baseline and subsequent follow-
up. PRP, platelet-rich plasma.
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We expected that our results would be lower than previous
ones (in terms of significance) since the average patient age
was older and only patients with late-stage OA were
included, with 58.5% of knees being classified as K-L grade
4. Nonetheless, in our study, the difference in VAS at 3 and
6 months was greater in the PRP group.
The primary objective of this study was to determine the
clinical utility of PRP IAI in the treatment of late-stage
knee OA for subjective pain relief 1 month after the infil-
tration compared with CSA infiltration, as determined by
by VAS. At 1 month, results showed a decrease in VAS in
both groups. Although there was no statistically significant
difference between groups, there was a 4-point decrease in
the control group compared with the study group. This
could be explained by the prompt anti-inflammatory effect
of corticosteroid. As expected, since corticosteroid effects
are known to be short, the VAS for the control group wors-
ened at 3 months while it improved in the study group. This
improvement decreased at 6 months, although remaining
above that for the control group (8-point difference at 3
and 6 months). Although this difference was not statisti-
cally significant, the fact that the study group had worse
OA involvement gives more value to the differences in
absolute numbers. Both treatments improved the initial
state as far as pain is concerned. These findings are con-
sistent with the recently published study of Forogh
et al,13 which also compared a single injection of PRP
with CSA. In a randomized double-blind clinical trial of
48 knees K-L grade 2 to 3, they found statistically signif-
icant differences between treatments as determined by
KOOS scores.13
Although we could not find statistically significant differ-
ences between groups in most of outcomes, our results did
not differ from published data6,11-13,25,27,29: PRP decreased
joint pain and improved activity of daily living and quality
of life in symptomatic knee OA.
TABLE 5
KOOS Scores Compared With Baseline at Follow-up for Both Groupsa
Baseline 1 mo
KOOS Subscale PRP Control P PRP Control P

































































3 mo 6 mo
KOOS Subscale PRP Control P PRP Control P

































































aData are provided as mean ± SD (range) and median [25th percentile, 75th percentile]. KOOS, Knee Injury and Osteoarthritis Outcome
Score; PRP, platelet-rich plasma.
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Several factors could explain the lower improvement of
our PRP results compared with previous randomized trials:
greater degree of knee OA, greater proportion of women
(72%), older mean age of participants (67 years), and higher
mean BMI (31 kg/m2)—all risk factors for symptomatic
knee OA.1 Kon et al19 observed superior effectiveness of
PRP in young men and patients with low BMI. Other stud-
ies6,13,25,27,29,32 with a greater proportion of women found
no differences between sexes. However, in our study, the
mean age of the patients was greater than 65 years, and
therefore, the results could be subdued. Furthermore, the
mean BMI of our sample was 31 kg/m2, meaning most
patients were class I obese. The mean BMIs of patients in
other published series11,13,19,25,27,32 ranged from 25 to 30 kg/
m2, but with few overweight patients. In the trial by Forogh
et al,13 which, like ours, compared PRP with CSA, partici-
pants had a mean age 61 years and mean BMI of 29 kg/m2,
lower than that in our series.
Unlike others studies,6,21,23,25,27,29,32 Filardo et al11,12 did
not find that PRP was superior to an active control. As
mentioned by these authors, this could be explained by the
use of a leukocyte-rich PRP.
In general, published data regarding PRP injections for
knee OA have not analyzed its clinical efficacy in advanced-
stage knee OA. Our study shows that, although only in
absolute numbers, PRP treatment tends to improve pain
and patient satisfaction at 6-month follow-up. Patient sat-
isfaction was very good or good in 73.53% of the study group
and 56.67% of the control group, and dissatisfaction was
greater in the control (43.33% regular or poor) than in the
study group (26.47% regular or poor).
Based on our results and noting that most published
studies observed that PRP effectiveness lasts 6 to
12 months on average,5,7,18,21-23,31 we might consider more
than 1 PRP IAI to treat late-stage knee OA, and, as Patel
et al25 and Gobbi et al15 have proposed, perform a cyclic
treatment. Patel et al25 found that a single dose of PRP was
as effective as a double dose at an interval of 3 weeks and
therefore propose a serial single injection at 6-month or
1-year intervals to relieve symptoms for longer periods.
Gobbi et al15 found that patients who received a second
cycle after 1 year improved beyond 18 to 24 months. Since
we could not find statistical differences between groups in
most of the outcomes, we believe that for late-stage knee
OA, a serial single injection of high-concentration PRP
(PAW classification type 4) might reduce the pain enough
and for longer periods, with an adequate quality of life, to
delay knee replacement.
Our study has several limitations. Although a sample
size calculation was performed to detect a reduction of 17
points in the treatment group versus the control group,
given that pain is a difficult variable to quantify, the sam-
ple might need to be larger. Given that there is no differ-
ence in these 2 groups in such a small population, the study
could be underpowered and a type II error cannot be ruled
out. Note that we did not achieve our target enrollment of
32 patients in the control group. We might look for more
objective parameters like joint inflammatory biochemical
markers or biomechanical studies to determine the clinical
improvement. Another limitation was the lack of imaging
assessment to evaluate OA progression, but we consider
that in late-stage knee OA, clinical improvement is more
valuable than radiographic progression of the disease. The
specificity of our work is the homogeneity of the sample:
Only patients with K-L grade 3 or 4 OA with enough symp-
toms to receive joint replacement were included.
A large randomized clinical trial using a therapeutic
regimen based on a serial single injection every 6 months,
with objective indicators and imaging assessment to
evaluate OA progression, is needed to further assess the
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Figure 3. Trends in mean Knee injury and Osteoarthritis Outcome Score (KOOS) results of both groups at baseline and subsequent
follow-ups. PRP, platelet-rich plasma.
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TABLE 6
SF-36 Scores Compared With Baseline at Follow-up for Both Groupsa
SF-36 Subscale
Baseline 1 mo
PRP Control P PRP Control P


































































































































3 mo 6 mo
SF-36 Subscale PRP Control P PRP Control P
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CONCLUSION
A single PRP intra-articular injection is effective for reliev-
ing pain and improving activity of daily living and quality of
life in patients with late-stage knee OA. For patients with
late-stage knee OA who are 67 years or older, 1 intra-
articular injection of PRP has similar results to 1 shot of
corticosteroid.
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